Stockreport

CSL Limited falls after Phase 3 setback for key trial [Seeking Alpha]

CSL LTD SP/ADR  (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
PDF The global trial was designed to evaluate serum protein CSL112 against a placebo to reduce the risk of major adverse cardiovascular events such as stroke in patients af [Read more]